Compare iShares Russell 2000 ETF (IWM) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs Merck & Co., Inc. — how do they compare? iShares Russell 2000 ETF trades at $278.75 (market cap $77.70B), while Merck & Co., Inc. trades at $145.09 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 4.5× iShares Russell 2000 ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while iShares Russell 2000 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and Merck & Co., Inc. for 98 Days on average.
| IWM | MRK | |
|---|---|---|
Market Cap | $77.70B | $351.28B |
Volume | 35,598,983 | 7,969,665 |
52-Week High | $305.06 | $156.43 |
52-Week Low | $229.13 | $82.49 |
Typical Hold Time | 83 Days | 98 Days |
Sector | — | Health |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM trades at $278.05, up 0.12% with bearish technical signals from moving averages. The small-cap ETF faces headwinds from Federal Reserve rate hikes and underperformance relative to large-cap indices. Recent news highlights IWM's decade-long trailing of the S&P 500 while carrying higher risk, with institutional selling pressure evident from Envestnet's 4.6% stake reduction in Q3 2026.
Small-cap exposure offers diversification but faces near-term pressure from tightening financial conditions. The ETF's broad Russell 2000 composition includes unprofitable companies, creating performance drag. Upside potential exists if economic conditions improve, but current momentum favors large-caps amid rising interest rates and energy price volatility.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
